Because persistent TLR4 signaling sustains tolerogenic macrophage states in cirrhosis, TLR4 inhibition reduces immunosuppressive mediators and improves antitumor responses, making it a plausible partner in combination regimens (155). Here, TLR4 is linked to Cirrhosis.